Dr. Peter Grandsard is currently an Executive Director of Research at Amgen responsible for the characterization of pre-clinical therapeutic candidates. Since joining Amgen in 1996, he has had a variety of roles and responsibilities. Trained as a chemical engineer (BE/ME) and as an analytical chemist (Ph.D.), he started as a scientist designing and implementing new laboratory automation and instrumentation. Later he led that team of engineers, physicists, biologists, and chemists, to increase therapeutics discovery and development efficiency, or to enable new activities. In 2011, Peter started leading another diverse organization (DAS, Discovery Attribute Sciences) with a remit to analyze therapeutic candidates and reagents, biologics or synthetics alike, in order to understand their structures, their physical-chemical attributes, and their protein target binding properties. Given his role, it is no surprise that Peter follows evolution in instrumentation and information technologies very closely, with more and more focus on machine learning for in-silico prediction of attributes.